An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.
A major breakthrough in cancer genetics has been achieved, paving the way for more effective prevention, early detection, and treatment strategies for patients with BRCA2 mutations.